Company: INDP
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001641172-25-023333
Chunk: 58

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 1
Chunk 58
---

income, net includes interest earned on deposits and investments and other items of income and gain and loss that are incidental to the core operations of the Company.

3

Results
of Operations

Three
months ended June 30, 2025 compared to three months ended June 30, 2024

The
following tables set forth our results of operations for the three months ended June 30, 2025 and 2024 and the relative dollar change
between the two periods.

    Three months ended  

    June 30,  
    Change 

    2025  
    2024  
    ($)  
    % 
  
    Operating expenses: 

    Research and development 
    $2,167,114  
    $1,713,973  
    $453,141  
     26.4%
  
    General and administrative 
     2,289,649  
     2,394,912  
     (105,263) 
     (4.4)%

    Total operating expenses 
     4,456,763  
     4,108,885  
     347,878  
     8.5%

    Loss from operations 
     (4,456,763) 
     (4,108,885) 
     (347,878) 
     8.5%

    Other income, net 
     15,547  
     93,618  
     (78,071) 
     (83.4)%
  
    Change in fair value of convertible promissory notes 
     (787,703) 
     -  
     (787,703) 
     - 

    Net loss 
    $(5,228,919) 
    $(4,015,267) 
    $(1,213,652) 
     30.2%
  
    Net loss attributable to common stockholders per share, basic and diluted 
    $(9.09) 
    $(13.16) 
    $4.07  
     (30.9)%
  
    Weighted average number of shares used in calculating net loss per share, basic and diluted 
     574,923  
     305,140  

Research
and Development Expenses

Research
and development expenses were approximately $2.2 million for the three months ended June 30,